CRISPR Therapeutics AG (NASDAQ:CRSP)

Stock Price: $64.66

+0.81 (1.27%)

Updated May 26, 2023 08:00 PM GMT+0000

Featured app

Invest now

77% of retail CFD accounts lose money.

Overview

Financials

Statistics

Profile

Chart

Market Cap	5.10B
Revenue	100.26M
Gross Profit	100.26M
Shares Out	78.94M
EPS (ttm)	-6.71
PE Ratio	-9.7399
Forward PE	-9.6693
Dividend Rate (ttm)	0.0000
Dividend Yield	0.0000

Trading Day	May 26
Last Price	$64.66
Previous Close	$63.85
Change ($)	0.81
Change (%)	1.27%
Day's Open	63.78
Day's Range	62.9 - 65.5
Day's Volume	1.02M
52 Week Range	38.94 - 86.95

About CRISPR Therapeutics AG

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA.

CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc.

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

For more information, please visit www.crisprtx.com.

News

Top biotech stocks to watch in 2022 December 29, 2021

CRISPR price outlook: RBC sees upside to $117 October 13, 2021

Quick info

Country

Industry

Biological Product (except Diagnostic) Manufacturing

Sector

Manufacturing

Employees

304

CEO

Samarth Kulkarni

Address

Baarerstrasse 14
Zug
Zug
6300

Phone

41415613277

Website

www.crisprtx.com

Ticker Symbol

CRSP

Exchange

NASDAQ Stock Exchange

Reporting Currency

USD

CRISPR Therapeutics AG income statements (2022) (USD)

	August 2022	August 2022	May 2022	February 2022
Total Revenue	158K	158K	0.94M	12.90M
Cost of Revenue	0	0	0	0
Gross Profit	158K	158K	0.94M	12.90M
Research & Development	123.22M	123.22M	118.25M	134.47M
Selling General & Admin	26.27M	26.27M	28.02M	24.13M
Operating Expense	183.42M	183.42M	176.91M	158.60M
Operating Income	-183.26M	-183.26M	-175.97M	-145.7M
Other Income Expense Net	0	0	0	0
EBIT	-183.26M	-183.26M	-175.97M	-145.7M
Interest Income	0	0	0	0
Pretax Income	-179.72M	-179.72M	-175.61M	-143.5M
Income Tax	6.12M	6.12M	3.61M	-2.25M
Minority Interest	0	0	0	0
Net Income	-185.83M	-185.83M	-179.22M	-141.25M
Net Income Basic	-185.83M	-185.83M	-179.22M	-141.25M

CRISPR Therapeutics AG income statements (2021) (USD)

	November 2021	July 2021	April 2021	February 2021
Total Revenue	824K	0.90B	539K	370K
Cost of Revenue	0	0	0	0
Gross Profit	824K	0.90B	539K	370K
Research & Development	105.32M	108.28M	90.57M	82.37M
Selling General & Admin	24.35M	29.81M	24.52M	25.77M
Operating Expense	129.67M	138.08M	115.08M	108.13M
Operating Income	-128.85M	762.62M	-114.54M	-107.76M
Other Income Expense Net	0	0	0	0
EBIT	-128.85M	762.62M	-114.54M	-107.76M
Interest Income	0	0	0	0
Pretax Income	-127.75M	763.37M	-112.59M	-107.19M
Income Tax	-595K	4.14M	575K	-147K
Minority Interest	0	0	0	0
Net Income	-127.15M	759.23M	-113.16M	-107.04M
Net Income Basic	-127.15M	759.23M	-113.16M	-107.04M

CRISPR Therapeutics AG income statements (2020) (USD)

	October 2020	September 2020	June 2020	March 2020	March 2020
Total Revenue	148K	N.A	N.A	N.A	N.A
Cost of Revenue	0	N.A	N.A	N.A	N.A
Gross Profit	148K	N.A	N.A	N.A	N.A
Research & Development	71.01M	68.67M	57.19M	52.09M	52.09M
Selling General & Admin	21.54M	21.54M	21.35M	19.55M	19.55M
Operating Expense	92.55M	N.A	N.A	N.A	N.A
Operating Income	-92.4M	-92.4M	-80.69M	-73.59M	-73.59M
Other Income Expense Net	0	160K	1.41M	4.23M	4.23M
EBIT	-92.4M	-92.4M	-80.69M	-73.59M	-73.59M
Interest Income	0	N.A	N.A	N.A	N.A
Pretax Income	-92.24M	-92.24M	-79.28M	-69.35M	-69.35M
Income Tax	200K	200K	379K	377K	377K
Minority Interest	0	0	0	0	0
Net Income	-92.44M	-92.44M	-79.66M	-69.73M	-69.73M
Net Income Basic	-92.44M	-92.44M	-79.66M	-69.73M	-69.73M

CRISPR Therapeutics AG income statements (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Total Revenue	N.A	N.A	N.A	N.A
Cost of Revenue	N.A	N.A	N.A	N.A
Gross Profit	N.A	N.A	N.A	N.A
Research & Development	47.33M	55.96M	39.53M	33.82M
Selling General & Admin	17.27M	15.52M	14.57M	13.93M
Operating Expense	N.A	N.A	N.A	N.A
Operating Income	10.98M	139.16M	-54.98M	-48.42M
Other Income Expense Net	19.56M	-466K	1.37M	100K
EBIT	10.98M	139.16M	-54.98M	-48.42M
Interest Income	N.A	N.A	N.A	N.A
Pretax Income	30.55M	138.70M	-53.61M	-48.32M
Income Tax	4K	274K	85K	85K
Minority Interest	0	0	0	0
Net Income	30.54M	138.42M	-53.7M	-48.41M
Net Income Basic	30.54M	138.42M	-53.7M	-48.41M

CRISPR Therapeutics AG income statements (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Total Revenue	N.A	N.A	N.A	N.A
Cost of Revenue	N.A	N.A	N.A	N.A
Gross Profit	N.A	N.A	N.A	N.A
Research & Development	28.80M	39.82M	25.63M	19.52M
Selling General & Admin	15.60M	9.29M	11.88M	8.01M
Operating Expense	N.A	N.A	N.A	N.A
Operating Income	-45.23M	-49.43M	-37.29M	-27M
Other Income Expense Net	-2.13M	-1.14M	-1M	-1.22M
EBIT	-45.23M	-49.43M	-37.29M	-27M
Interest Income	N.A	N.A	N.A	N.A
Pretax Income	-47.36M	-50.57M	-38.28M	-28.21M
Income Tax	234K	137K	96K	86K
Minority Interest	0	0	0	0
Net Income	-47.59M	-50.71M	-38.38M	-28.3M
Net Income Basic	-47.59M	-50.71M	-38.38M	-28.3M

CRISPR Therapeutics AG income statements (2017) (USD)

	December 2017	September 2017	June 2017
Total Revenue	N.A	N.A	N.A
Cost of Revenue	N.A	N.A	N.A
Gross Profit	N.A	N.A	N.A
Research & Development	20.03M	17.85M	17.12M
Selling General & Admin	10.44M	7.31M	7.06M
Operating Expense	N.A	N.A	N.A
Operating Income	0.97M	-23.57M	-21.31M
Other Income Expense Net	-413K	-430K	-666K
EBIT	0.97M	-23.57M	-21.31M
Interest Income	N.A	N.A	N.A
Pretax Income	559K	-24M	-21.97M
Income Tax	419K	707K	343K
Minority Interest	0	0	0
Net Income	140K	-24.71M	-22.32M
Net Income Basic	140K	-24.71M	-22.32M

CRISPR Therapeutics AG balance sheet (2023) (USD)

	February 2023
Current Cash	1.82B
Receivables	0
Inventory	0
Current Assets	1.85B
Other Current Assets	37.71M
Short Term Investments	37.71M
Long Term Investments	390.03M
Property/Plant Equipment	163.63M
Good Will	N.A
Intangible Assets	71K
Tangible Assets (Net)	1.88B
Other Assets	4.64M
Total Assets	2.24B
Accounts Payable	27.43M
Other Current Liabilities	93.68M
Total Current Liabilities	121.11M
Total Liabilities	367.58M
Long Term Debt	0
Current Long Term Debt	0
Minority Interest	0
Common Stock	78.35M
Treasury Stock	-63K
Retained Earnings	-846.09M
Capital Surplus	N.A
Shareholder Equity	1.88B
Other Liabilities	N.A

CRISPR Therapeutics AG balance sheet (2022) (USD)

	August 2022	August 2022	May 2022	February 2022
Current Cash	2.07B	2.07B	2.22B	2.38B
Receivables	66K	66K	143K	305K
Inventory	0	0	0	0
Current Assets	2.11B	2.11B	2.26B	2.42B
Other Current Assets	41.65M	41.65M	39.21M	38.08M
Short Term Investments	41.65M	41.65M	39.21M	38.08M
Long Term Investments	356.31M	356.31M	345.56M	334.36M
Property/Plant Equipment	165.19M	165.19M	157.45M	137.58M
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	98K	98K	112K	125K
Tangible Assets (Net)	2.09B	2.09B	2.24B	2.40B
Other Assets	3.76M	3.76M	4.33M	5.29M
Total Assets	2.46B	2.46B	2.61B	2.75B
Accounts Payable	25.24M	25.24M	27.11M	14.82M
Other Current Liabilities	94.71M	94.71M	86.59M	105.07M
Total Current Liabilities	119.96M	119.96M	113.70M	119.88M
Total Liabilities	372.53M	372.53M	361.26M	352.42M
Long Term Debt	0	0	0	0
Current Long Term Debt	0	0	0	0
Minority Interest	0	0	0	0
Common Stock	77.51M	77.51M	77.10M	76.67M
Treasury Stock	-63K	-63K	-63K	-63K
Retained Earnings	-560.97M	-560.97M	-375.13M	-195.92M
Capital Surplus	N.A	N.A	N.A	N.A
Shareholder Equity	2.09B	2.09B	2.24B	2.40B
Other Liabilities	N.A	N.A	N.A	N.A

CRISPR Therapeutics AG balance sheet (2021) (USD)

	November 2021	July 2021	April 2021	February 2021
Current Cash	2.48B	2.59B	1.81B	1.69B
Receivables	152K	150K	150K	144K
Inventory	0	0	0	0
Current Assets	2.52B	2.62B	1.83B	1.72B
Other Current Assets	41.42M	31.35M	26.01M	26.14M
Short Term Investments	41.42M	31.35M	26.01M	26.14M
Long Term Investments	302.79M	278.58M	125.55M	111.35M
Property/Plant Equipment	105.88M	75.41M	51.91M	42.16M
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	139K	153K	167K	180K
Tangible Assets (Net)	2.51B	2.60B	1.81B	1.66B
Other Assets	4.79M	5.56M	6.50M	1.29M
Total Assets	2.82B	2.90B	1.96B	1.83B
Accounts Payable	10.17M	10.15M	13.07M	9.09M
Other Current Liabilities	86.04M	89.78M	70.02M	85.17M
Total Current Liabilities	96.21M	99.92M	83.09M	94.26M
Total Liabilities	308.80M	295.72M	152.41M	163.73M
Long Term Debt	0	0	0	0
Current Long Term Debt	0	0	0	0
Minority Interest	0	0	0	0
Common Stock	76.29M	75.83M	75.01M	71.39M
Treasury Stock	-63K	-63K	-63K	-63K
Retained Earnings	-54.67M	72.49M	-686.74M	-573.58M
Capital Surplus	N.A	N.A	N.A	N.A
Shareholder Equity	2.51B	2.60B	1.81B	1.66B
Other Liabilities	N.A	N.A	N.A	N.A

CRISPR Therapeutics AG balance sheet (2020) (USD)

	October 2020	September 2020	June 2020	March 2020	March 2020
Current Cash	1.37B	1.04B	0.95B	889.71M	889.71M
Receivables	110K	110K	33K	25.12M	25.12M
Inventory	0	N.A	N.A	N.A	N.A
Current Assets	1.39B	1.39B	0.97B	0.93B	0.93B
Other Current Assets	24.84M	24.84M	20.52M	14.45M	14.45M
Short Term Investments	24.84M	324.57M	N.A	N.A	N.A
Long Term Investments	94.08M	16.85M	6.30M	5.04M	5.04M
Property/Plant Equipment	37.92M	76.38M	73.74M	72.09M	72.09M
Good Will	N.A	N.A	N.A	N.A	N.A
Intangible Assets	194K	194K	208K	221K	221K
Tangible Assets (Net)	1.34B	1.34B	0.91B	886.10M	886.10M
Other Assets	662K	662K	662K	662K	662K
Total Assets	1.49B	1.49B	1.05B	1.01B	1.01B
Accounts Payable	19.02M	19.02M	13.22M	11.28M	11.28M
Other Current Liabilities	65.13M	48.14M	49.87M	34.52M	34.52M
Total Current Liabilities	84.15M	84.15M	74.51M	55.09M	55.09M
Total Liabilities	141.72M	141.72M	135.86M	121.20M	121.20M
Long Term Debt	0	38.57M	40.32M	42.39M	42.39M
Current Long Term Debt	0	N.A	N.A	N.A	N.A
Minority Interest	0	0	0	0	0
Common Stock	1.81B	70.60M	62.55M	60.89M	60.89M
Treasury Stock	-63K	63K	63K	63K	63K
Retained Earnings	-466.54M	-466.54M	-374.1M	-294.44M	-294.44M
Capital Surplus	N.A	1.81B	1.28B	1.18B	1.18B
Shareholder Equity	1.34B	1.34B	0.91B	886.10M	886.10M
Other Liabilities	N.A	N.A	N.A	N.A	N.A

CRISPR Therapeutics AG balance sheet (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Current Cash	0.94B	629.72M	427.89M	437.55M
Receivables	99K	39K	321K	331K
Inventory	N.A	N.A	N.A	N.A
Current Assets	0.96B	664.07M	438.47M	449.80M
Other Current Assets	14.58M	34.31M	10.27M	11.92M
Short Term Investments	N.A	N.A	N.A	N.A
Long Term Investments	5.04M	3.92M	3.92M	3.16M
Property/Plant Equipment	72.83M	51.69M	50.93M	43.97M
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	235K	249K	262K	276K
Tangible Assets (Net)	0.94B	591.88M	367.68M	379.81M
Other Assets	26.10M	668K	669K	669K
Total Assets	1.07B	720.59M	494.25M	497.87M
Accounts Payable	5.94M	3.37M	7.14M	7.13M
Other Current Liabilities	42.09M	70.12M	18.85M	15.75M
Total Current Liabilities	57.11M	79.78M	31.41M	28.40M
Total Liabilities	127.33M	128.71M	126.56M	118.06M
Long Term Debt	44.05M	36.83M	37.20M	31.73M
Current Long Term Debt	N.A	N.A	N.A	N.A
Minority Interest	0	0	0	0
Common Stock	60.78M	55.19M	53.50M	52.64M
Treasury Stock	63K	57K	57K	57K
Retained Earnings	-224.71M	-255.25M	-393.68M	-339.98M
Capital Surplus	1.16B	845.53M	759.80M	718.26M
Shareholder Equity	0.94B	591.88M	367.68M	379.81M
Other Liabilities	N.A	N.A	N.A	N.A

CRISPR Therapeutics AG balance sheet (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Current Cash	456.65M	487.30M	N.A	341.77M
Receivables	88K	552K	0.94M	1.26M
Inventory	N.A	N.A	N.A	N.A
Current Assets	466.40M	496.69M	330.55M	351.48M
Other Current Assets	9.66M	8.84M	9.87M	8.45M
Short Term Investments	N.A	N.A	N.A	N.A
Long Term Investments	3.16M	3.17M	3.17M	3.17M
Property/Plant Equipment	18.50M	18.10M	18.40M	18.91M
Good Will	N.A	N.A	N.A	N.A
Intangible Assets	289K	303K	317K	331K
Tangible Assets (Net)	392.20M	417.31M	265.15M	290.34M
Other Assets	669K	650K	704K	571K
Total Assets	489.02M	518.90M	353.13M	374.45M
Accounts Payable	5.07M	5.22M	4.48M	2.55M
Other Current Liabilities	22.28M	27.03M	13.96M	11.42M
Total Current Liabilities	27.75M	32.28M	18.48M	14.40M
Total Liabilities	96.82M	101.59M	87.98M	84.12M
Long Term Debt	N.A	N.A	N.A	N.A
Current Long Term Debt	N.A	N.A	N.A	N.A
Minority Interest	0	0	0	0
Common Stock	51.85M	51.55M	47.07M	46.68M
Treasury Stock	57K	57K	50K	N.A
Retained Earnings	-291.57M	-243.98M	-193.27M	-154.89M
Capital Surplus	682.25M	659.78M	457.03M	443.77M
Shareholder Equity	392.20M	417.31M	265.15M	290.34M
Other Liabilities	N.A	N.A	N.A	N.A

CRISPR Therapeutics AG balance sheet (2017) (USD)

	December 2017	September 2017	June 2017
Current Cash	239.76M	253.52M	272.26M
Receivables	2.63M	3.21M	6.81M
Inventory	N.A	N.A	N.A
Current Assets	248.39M	258.59M	281.29M
Other Current Assets	6M	1.86M	2.21M
Short Term Investments	N.A	N.A	N.A
Long Term Investments	3.15M	3.15M	3.15M
Property/Plant Equipment	18.86M	19.56M	19.93M
Good Will	N.A	N.A	N.A
Intangible Assets	344K	358K	372K
Tangible Assets (Net)	187.29M	178.96M	197.80M
Other Assets	606K	657K	237K
Total Assets	271.35M	282.32M	304.98M
Accounts Payable	1.64M	2.12M	2.56M
Other Current Liabilities	12.53M	9.57M	12.98M
Total Current Liabilities	14.51M	12.12M	15.81M
Total Liabilities	83.51M	103.36M	107.17M
Long Term Debt	N.A	N.A	N.A
Current Long Term Debt	N.A	N.A	N.A
Minority Interest	0	0	0
Common Stock	40.59M	40.38M	40.04M
Treasury Stock	N.A	N.A	N.A
Retained Earnings	-125.44M	-125.58M	-100.87M
Capital Surplus	312.02M	303.29M	297.45M
Shareholder Equity	187.83M	178.96M	197.80M
Other Liabilities	N.A	N.A	N.A

CRISPR Therapeutics AG cash flow (2023) (USD)

	February 2023
Net Income	-110.58M
Depreciation	5.85M
Changes in Receivables	0
Changes in Inventories	0
Cash Change	1.82B
Cash Flow	-113.33M
Capital Expenditures	-6.19M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-175.53M
Dividends Paid	N.A
Net Borrowings	-1.85B
Other Financing Cash Flows	N.A
Cash Flow Financing	2.48M
Exchange Rate Effect	N.A

CRISPR Therapeutics AG cash flow (2022) (USD)

	November 2022	August 2022
Net Income	-174.55M	-185.83M
Depreciation	5.02M	7.27M
Changes in Receivables	49K	66K
Changes in Inventories	0	0
Cash Change	1.90B	2.07B
Cash Flow	-105.22M	-141.96M
Capital Expenditures	-6.02M	-9.63M
Investments	N.A	N.A
Investing Activity (other)	N.A	N.A
Total Investing Cash Flows	87.46M	-56.07M
Dividends Paid	N.A	N.A
Net Borrowings	-1.93B	-2.11B
Other Financing Cash Flows	N.A	N.A
Cash Flow Financing	15.11M	10.35M
Exchange Rate Effect	N.A	N.A

CRISPR Therapeutics AG cash flow (2021) (USD)

	November 2021
Net Income	-127.15M
Depreciation	5.32M
Changes in Receivables	152K
Changes in Inventories	0
Cash Change	2.48B
Cash Flow	1.33B
Capital Expenditures	-37.05M
Investments	N.A
Investing Activity (other)	N.A
Total Investing Cash Flows	-565.18M
Dividends Paid	N.A
Net Borrowings	-2.52B
Other Financing Cash Flows	N.A
Cash Flow Financing	10.21M
Exchange Rate Effect	N.A

CRISPR Therapeutics AG cash flow (2020) (USD)

	October 2020	September 2020	June 2020	March 2020
Net Income	-92.44M	-92.44M	-79.66M	-69.73M
Depreciation	6.62M	2.34M	2.19M	2.09M
Changes in Receivables	77K	-77K	25.08M	-25.02M
Changes in Inventories	0	N.A	N.A	N.A
Cash Change	420.92M	106.89M	56.62M	-54.06M
Cash Flow	-157.15M	-75.7M	-29.28M	-52.18M
Capital Expenditures	-12.12M	-5.52M	-3.61M	-2.99M
Investments	N.A	-324.81M	N.A	N.A
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-336.93M	-330.33M	-3.61M	-2.99M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	-1.39B	N.A	N.A	N.A
Other Financing Cash Flows	N.A	N.A	N.A	N.A
Cash Flow Financing	603.53M	512.89M	89.51M	1.13M
Exchange Rate Effect	N.A	33K	-3K	-25K

CRISPR Therapeutics AG cash flow (2019) (USD)

	December 2019	September 2019	June 2019	March 2019
Net Income	30.54M	138.42M	-53.7M	-48.41M
Depreciation	1.43M	1.28M	1.20M	812K
Changes in Receivables	-60K	282K	10K	-243K
Changes in Inventories	N.A	N.A	N.A	N.A
Cash Change	315.18M	201.83M	-8.91M	-19.1M
Cash Flow	3.38M	133.42M	-36.38M	-43.74M
Capital Expenditures	-0.95M	-2.46M	-2.17M	-1.1M
Investments	N.A	N.A	N.A	N.A
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	7.06M	-2.46M	-2.17M	-1.1M
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	N.A	N.A	N.A	N.A
Other Financing Cash Flows	N.A	N.A	N.A	N.A
Cash Flow Financing	304.72M	70.89M	29.65M	25.73M
Exchange Rate Effect	29K	-12K	-10K	8K

CRISPR Therapeutics AG cash flow (2018) (USD)

	December 2018	September 2018	June 2018	March 2018
Net Income	-47.59M	-50.71M	-38.38M	-28.3M
Depreciation	0.95M	883K	865K	826K
Changes in Receivables	464K	392K	316K	1.37M
Changes in Inventories	N.A	N.A	N.A	N.A
Cash Change	-30.65M	167.56M	-22.03M	102.02M
Cash Flow	-28.37M	-19.96M	-25.22M	-22.69M
Capital Expenditures	-1M	-695K	-523K	-555K
Investments	N.A	N.A	N.A	N.A
Investing Activity (other)	N.A	N.A	N.A	N.A
Total Investing Cash Flows	-1M	-695K	-523K	-555K
Dividends Paid	N.A	N.A	N.A	N.A
Net Borrowings	N.A	N.A	N.A	N.A
Other Financing Cash Flows	N.A	N.A	N.A	N.A
Cash Flow Financing	-1.27M	188.22M	3.73M	125.25M
Exchange Rate Effect	-7K	-6K	-21K	12K

CRISPR Therapeutics AG cash flow (2017) (USD)

	December 2017	September 2017	June 2017
Net Income	140K	-24.71M	-22.32M
Depreciation	806K	792K	706K
Changes in Receivables	585K	3.60M	-1.14M
Changes in Inventories	N.A	N.A	N.A
Cash Change	-13.76M	-18.75M	-16.61M
Cash Flow	-14.84M	-15.87M	-15.97M
Capital Expenditures	-205K	-2.99M	-1.33M
Investments	N.A	-500K	N.A
Investing Activity (other)	N.A	N.A	N.A
Total Investing Cash Flows	-205K	-3.49M	-1.33M
Dividends Paid	N.A	N.A	N.A
Net Borrowings	N.A	N.A	-3K
Other Financing Cash Flows	N.A	N.A	N.A
Cash Flow Financing	1.28M	609K	692K
Exchange Rate Effect	2K	8K	2K